

Information on this form is a guide only. User will be solely responsible for verifying its currency and accuracy with the corresponding BCCA treatment protocols located at www.bccancer.bc.ca and according to acceptable standards of care

PROTOCOL CODE: UBRAVKAD

A BCCA "Compassionate Access Program" request form must be completed and approved prior to treatment

DOCTOR'S ORDERS Htcm Wtkg B	SAm²
REMINDER: Please ensure drug allergies and previous bleomycin are documented or	the Allergy & Alert Form
DATE: To be given: Cycle :	# :
Date of Previous Cycle:	
☐ Delay Treatment week(s) ☐ CBC & Diff, Platelets day of treatment May proceed with doses as written if within 96 hours ANC greater than or equal to 1 x 10 ⁹ /L and Platelets greater than or equal to 75 x 10 ⁹ /L Dose modification for: ☐ Hematology ☐ Renal Function ☐ Other Toxicity Proceed with treatment based on blood work from	
PREMEDICATIONS: Patient to take own supply. RN/Pharmacist to confirm	
 □ prochlorperazine 10 mg PO prior to treatment □ metoclopramide 10 to 20 mg PO prior to treatment □ Other: 	
CHEMOTHERAPY:	
trastuzumab emtansine (KADCYLA) 3.6 mg/kg xkg =mg Dose Modification: mg/kg xkg = mg IV in 250 mL NS (use in-line filter) over 1 h 30 min. Observe for 1 hour 30 minutes post infusion. If no infusion reaction observed in Cycle 1, may administer subsequent cycles over 30 minutes, observe for 30 minutes post-infusion.	
RETURN APPOINTMENT ORDERS	
Return in three weeks for Doctor and Cycle	
Last Cycle. Return inweeks.	
CBC & Diff, platelets, bilirubin, LFTs prior to each cycle	
If clinically indicated: Tot. Prot Albumin Electrolytes Bilirubin GGT Alk Phos. AST LDH ALT BUN Creatinine Echocardiogram MUGA Scan	
☐ Other Tests: ☐ ECG ☐ Consults:	
☐ See general orders sheet for additional requests.	
DOCTOR'S SIGNATURE:	SIGNATURE:
	UC: